Abstract.
There is a lack of reliable predictors of the response to alkylating agents in children with idiopathic nephrotic syndrome (NS). HLA-DR7 is strongly associated with the frequency of relapses in steroid-sensitive NS before cytostatic therapy. We therefore examined retrospectively the time to the first relapse and the incidence of subsequent relapses in 54 HLA-typed children with frequently relapsing NS, after treatment with cyclophosphamide (n = 49) or chlorambucil (n = 5) for 8 or 12 weeks; 38 patients were HLA-DR7 positive and 16 negative with 80% in both groups being steroid dependent. HLA typing was performed using serological or DNA typing methods. Renal biopsy showed minimal glomerular changes. A lower proportion of HLA-DR7 positive than negative patients remained in remission after 3 years (36% vs. 81%, P<0.02) and 5 years (36% vs. 72%, P<0.03). In the first 3 years after cytostatic therapy the mean number of prednisone-treated relapses was 1.3/patient per year in HLA-DR7-positive patients compared with 0.4 in negative patients (P<0.025). There was no statistically significant difference in the proportion of relapse-free patients with and without steroid dependency. The HLA status predicts the response of NS patients to alkylating agents better than the rate of previous relapses.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received September 19, 1995; received in revised form and accepted April 16, 1996
Rights and permissions
About this article
Cite this article
Konrad, M., Mytilineos, J., Ruder, H. et al. HLA-DR7 predicts the response to alkylating agents in steroid-sensitive nephrotic syndrome. Pediatr Nephrol 11, 16–19 (1997). https://doi.org/10.1007/s004670050224
Issue Date:
DOI: https://doi.org/10.1007/s004670050224